|
AU2003225410A1
(en)
*
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
ES2351976T3
(es)
|
2003-04-29 |
2011-02-14 |
Avi Biopharma, Inc. |
Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células.
|
|
US20050222068A1
(en)
*
|
2003-10-23 |
2005-10-06 |
Mourich Dan V |
Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
|
|
EP1713332A4
(en)
*
|
2004-01-23 |
2010-08-18 |
Avi Biopharma Inc |
ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION
|
|
US20050288246A1
(en)
*
|
2004-05-24 |
2005-12-29 |
Iversen Patrick L |
Peptide conjugated, inosine-substituted antisense oligomer compound and method
|
|
SI2206781T1
(sl)
|
2004-06-28 |
2016-05-31 |
The University Of Western Australia |
Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe
|
|
US8129352B2
(en)
*
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
|
ES2852549T3
(es)
*
|
2005-02-09 |
2021-09-13 |
Sarepta Therapeutics Inc |
Composición antisentido para tratamiento de la atrofia muscular
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
WO2007030691A2
(en)
*
|
2005-09-08 |
2007-03-15 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating picornavirus infection
|
|
CA2638823A1
(en)
|
2006-02-13 |
2007-08-23 |
Alethia Biotherapeutics Inc. |
Polynucleotides and polypeptide sequences involved in the process of bone remodeling
|
|
US8168181B2
(en)
|
2006-02-13 |
2012-05-01 |
Alethia Biotherapeutics, Inc. |
Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
|
|
US8785407B2
(en)
*
|
2006-05-10 |
2014-07-22 |
Sarepta Therapeutics, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
DK2203173T3
(en)
|
2007-10-26 |
2016-02-29 |
Academisch Ziekenhuis Leiden |
Materials and methods for prevention of muscle diseases
|
|
CA2710013A1
(en)
*
|
2007-12-28 |
2009-07-09 |
Avi Biopharma, Inc. |
Immunomodulatory agents and methods of use
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US8231895B2
(en)
|
2008-05-22 |
2012-07-31 |
Universidade De Coimbra |
Targeted delivery to human diseases and disorders
|
|
US20110130346A1
(en)
*
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
US8575305B2
(en)
|
2008-06-04 |
2013-11-05 |
Medical Research Council |
Cell penetrating peptides
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
EP2762567B1
(en)
|
2008-10-24 |
2016-07-13 |
Sarepta Therapeutics, Inc. |
Multiple exon skipping compositions for DMD
|
|
US8592386B2
(en)
*
|
2008-12-17 |
2013-11-26 |
Sarepta Therapeutics, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
ES2593836T3
(es)
|
2009-04-24 |
2016-12-13 |
Biomarin Technologies B.V. |
Oligonucleótido que comprende una inosina para tratar la DMD
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
SMT201800579T1
(it)
|
2009-11-12 |
2019-01-11 |
Univ Western Australia |
Molecole antisenso e metodi per trattare patologie
|
|
CA2779830C
(en)
|
2009-11-13 |
2020-07-21 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating influenza viral infection
|
|
KR20120125455A
(ko)
*
|
2009-12-11 |
2012-11-15 |
광주과학기술원 |
세포내 타겟 결합용 바이포달 펩타이드 바인더
|
|
US9006415B2
(en)
*
|
2010-04-06 |
2015-04-14 |
Massachusetts Institute Of Technology |
Targeted delivery of nucleic acids
|
|
US9050373B2
(en)
*
|
2010-05-13 |
2015-06-09 |
The Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
|
|
JP2013530154A
(ja)
|
2010-05-28 |
2013-07-25 |
サレプタ セラピューティクス， インコーポレイテッド |
修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ
|
|
US20130225659A1
(en)
*
|
2010-07-19 |
2013-08-29 |
Isis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
|
US8198429B2
(en)
|
2010-08-09 |
2012-06-12 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
|
US9161948B2
(en)
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
WO2012150960A1
(en)
*
|
2011-05-05 |
2012-11-08 |
Avi Biopharma, Inc. |
Peptide oligonucleotide conjugates
|
|
WO2013030569A2
(en)
|
2011-08-30 |
2013-03-07 |
Michael John Gait |
Peptides
|
|
EP2750715B1
(en)
|
2011-08-30 |
2018-10-31 |
The Regents of The University of California |
Identification of small molecules that enhance therapeutic exon skipping
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
ES2535654T3
(es)
*
|
2011-10-13 |
2015-05-13 |
Association Institut De Myologie |
ADN triciclo-fosforotioato
|
|
PT2788487T
(pt)
|
2011-12-08 |
2018-07-03 |
Sarepta Therapeutics Inc |
Análogos de oligonucleótido visando lmna humano
|
|
ES2907250T3
(es)
|
2012-01-27 |
2022-04-22 |
Biomarin Tech Bv |
Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker
|
|
AU2013262709A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
SG11201407483YA
(en)
*
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating smn gene family expression
|
|
CA2873769A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating hemoglobin gene family expression
|
|
BR112014028634A2
(pt)
*
|
2012-05-16 |
2017-06-27 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão de utrn
|
|
BR112014028644A2
(pt)
|
2012-05-16 |
2017-08-15 |
Rana Therapeutics Inc |
Composições e métodos para modulação da expressão de atp2a2
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
KR101329411B1
(ko)
*
|
2012-05-31 |
2013-11-14 |
주식회사 엘지생활건강 |
피부투과성 펩타이드
|
|
ES2723885T3
(es)
|
2012-07-19 |
2019-09-03 |
Daiichi Sankyo Co Ltd |
Anticuerpos anti-Siglec-15
|
|
CA2882292C
(en)
|
2012-08-13 |
2023-10-17 |
The Rockefeller University |
Treatment and diagnosis of melanoma
|
|
MX369519B
(es)
*
|
2012-09-25 |
2019-11-11 |
Genzyme Corp |
Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica.
|
|
JP6452614B2
(ja)
|
2012-11-15 |
2019-01-16 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドコンジュゲート
|
|
CN103981147B
(zh)
|
2013-02-08 |
2017-11-10 |
中国科学院上海生命科学研究院 |
一种新的制备肝实质细胞的方法
|
|
AU2014236140B2
(en)
|
2013-03-14 |
2019-10-03 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
NZ732507A
(en)
|
2013-03-15 |
2018-08-31 |
Sarepta Therapeutics Inc |
Improved compositions for treating muscular dystrophy
|
|
US10010562B2
(en)
|
2013-11-06 |
2018-07-03 |
Merck Sharp & Dohme Corp. |
Dual molecular delivery of oligonucleotides and peptide containing conjugates
|
|
WO2015175977A2
(en)
|
2014-05-16 |
2015-11-19 |
Geller Bruce L |
Antisense antibacterial compounds and methods
|
|
EP3569252B1
(en)
|
2014-05-19 |
2021-12-15 |
Oregon State University |
Antisense antibacterial compounds and methods
|
|
US20170182189A1
(en)
*
|
2014-05-23 |
2017-06-29 |
Genzyme Corporation |
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
|
|
JP6825914B2
(ja)
|
2014-05-23 |
2021-02-03 |
ジェンザイム・コーポレーション |
ペプチド担体上の多重オリゴヌクレオチド部分
|
|
AU2015372560B2
(en)
*
|
2014-12-31 |
2021-12-02 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
|
MA41795A
(fr)
*
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
WO2016196897A1
(en)
|
2015-06-04 |
2016-12-08 |
Sarepta Therapeutics, Inc. |
Methods and compounds for treatment of lymphocyte-related diseases and conditions
|
|
WO2017062835A2
(en)
*
|
2015-10-09 |
2017-04-13 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
AU2016379399B2
(en)
|
2015-12-23 |
2022-12-08 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
|
AU2016379402B2
(en)
*
|
2015-12-23 |
2023-01-12 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
WO2017184529A1
(en)
|
2016-04-18 |
2017-10-26 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
NZ747685A
(en)
|
2016-04-29 |
2023-05-26 |
Sarepta Therapeutics Inc |
Oligonucleotide analogues targeting human lmna
|
|
KR102646318B1
(ko)
|
2016-12-19 |
2024-03-12 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
|
|
US10800817B2
(en)
|
2016-12-19 |
2020-10-13 |
Morehouse School Of Medicine |
Compositions and methods for treating diseases by inhibiting exosome release
|
|
HRP20240705T1
(hr)
*
|
2016-12-19 |
2024-08-30 |
Sarepta Therapeutics, Inc. |
Oligomerni konjugati koji preskaču egzon za mišićnu distrofiju
|
|
KR102810425B1
(ko)
|
2016-12-19 |
2025-05-21 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
|
|
SG10202107429WA
(en)
|
2017-01-06 |
2021-08-30 |
Avidity Biosciences Inc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
|
US20180207293A1
(en)
*
|
2017-01-25 |
2018-07-26 |
2C Tech Corp. |
Nanoparticles for sustained ophthalmic drug delivery and methods of use
|
|
GB201711809D0
(en)
*
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
EP3687519A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
EP3687577A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
TW202423453A
(zh)
|
2017-10-17 |
2024-06-16 |
美商薩羅塔治療公司 |
用於反義遞送之細胞穿透肽
|
|
EP3713575A4
(en)
|
2017-11-21 |
2021-08-25 |
Rgenix, Inc. |
POLYMORPHS AND THEIR USES
|
|
JP7013626B2
(ja)
*
|
2018-01-05 |
2022-02-01 |
国立医薬品食品衛生研究所長 |
細胞膜透過ペプチド、構築物、及び、カーゴ分子を細胞内に輸送する方法
|
|
US11987647B2
(en)
|
2018-05-09 |
2024-05-21 |
Ohio State Innovation Foundation |
Cyclic cell-penetrating peptides with one or more hydrophobic residues
|
|
EP3806868A4
(en)
|
2018-06-13 |
2022-06-22 |
Sarepta Therapeutics, Inc. |
EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
|
|
TW202449155A
(zh)
|
2018-07-27 |
2024-12-16 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US20210308272A1
(en)
*
|
2018-08-02 |
2021-10-07 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
GB201812980D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
GB201812972D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
EP3890783A1
(en)
|
2018-12-07 |
2021-10-13 |
Oxford University Innovation Limited |
Linkers
|
|
SG11202104960PA
(en)
|
2018-12-13 |
2021-06-29 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
GB201821269D0
(en)
|
2018-12-28 |
2019-02-13 |
Nippon Shinyaku Co Ltd |
Myostatin signal inhibitor
|
|
JP2022528725A
(ja)
|
2019-04-18 |
2022-06-15 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを治療するための組成物
|
|
GB201911403D0
(en)
*
|
2019-08-09 |
2019-09-25 |
Univ Oxford Innovation Ltd |
Conjugate and uses thereof
|
|
KR102270700B1
(ko)
*
|
2019-11-01 |
2021-06-30 |
한국과학기술연구원 |
폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
|
|
JP7689964B2
(ja)
|
2019-12-13 |
2025-06-09 |
インスピルナ，インコーポレーテッド |
金属塩及びその使用
|
|
AU2020411964A1
(en)
|
2019-12-26 |
2022-06-16 |
National Center Of Neurology And Psychiatry |
Antisense nucleic acid that induces skipping of exon 50
|
|
PE20230237A1
(es)
|
2020-02-28 |
2023-02-07 |
Nippon Shinyaku Co Ltd |
Acidos nucleicos antisentido que inducen la omision del exon 51
|
|
US11987795B2
(en)
|
2020-11-24 |
2024-05-21 |
The Broad Institute, Inc. |
Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
|
|
US20240327831A1
(en)
|
2020-12-23 |
2024-10-03 |
Sarepta Therapeutics, Inc. |
Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
|
|
IL307937A
(en)
|
2021-04-30 |
2023-12-01 |
Sarepta Therapeutics Inc |
Treatment methods for muscular dystrophy
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
AU2022298028A1
(en)
|
2021-06-23 |
2023-12-21 |
National Center Of Neurology And Psychiatry |
Combination of antisense oligomers
|
|
JPWO2023282344A1
(enExample)
|
2021-07-08 |
2023-01-12 |
|
|
|
IL310003A
(en)
|
2021-07-08 |
2024-03-01 |
Nippon Shinyaku Co Ltd |
Nephrotoxicity reducing agent
|
|
WO2023282346A1
(ja)
|
2021-07-08 |
2023-01-12 |
日本新薬株式会社 |
析出抑制剤
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US20250011777A1
(en)
*
|
2021-09-03 |
2025-01-09 |
Sarepta Therapeutics, Inc. |
Delivery of anitsense oligomers by mirror image peptides
|
|
JP2025509438A
(ja)
|
2022-03-17 |
2025-04-11 |
サレプタ セラピューティクス， インコーポレイテッド |
ホスホロジアミデートモルホリノオリゴマーコンジュゲート
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
WO2023205451A1
(en)
|
2022-04-22 |
2023-10-26 |
Entrada Therapeutics, Inc. |
Cyclic peptides for delivering therapeutics
|
|
WO2024091824A1
(en)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|
|
JP2025537104A
(ja)
|
2022-11-02 |
2025-11-14 |
サレプタ セラピューティクス， インコーポレイテッド |
アンチセンスオリゴマーコンジュゲートの製剤化
|
|
WO2024129459A1
(en)
|
2022-12-16 |
2024-06-20 |
University Of Rochester |
Repairmen! of barrier dysfunction in esophagus
|
|
WO2025085868A2
(en)
|
2023-10-20 |
2025-04-24 |
Radiation Control Technologies, Inc. |
Cd47-targeting morpholinos
|